Celyad Oncology represents a commitment to innovative cell-based therapies for cancer treatment. The company's corporate philosophy revolves around leveraging its expertise in cell engineering and immune-oncology to develop groundbreaking therapies. Celyad Oncology aims to improve patient outcomes and quality of life by delivering personalized and targeted treatments. With a strong focus on research and development, Celyad Oncology strives to stay at the forefront of medical advancements, collaborating with scientific and clinical partners to advance the field of cellular immunotherapy. The company's dedication to scientific rigor and a patient-centric approach drives its pursuit of transformative solutions in the fight against cancer.

Celyad Oncology is primarily present in multiple countries and regions around the globe. With a strong global presence, the company operates in key markets such as Europe, the United States, and Asia. Celyad Oncology's commitment to advancing cell-based therapies extends to various regions, allowing it to reach a wide patient population in pursuit of innovative treatments for various oncology indications.

Celyad Oncology, a leading biopharmaceutical company, has achieved several significant milestones. One notable accomplishment is the successful completion of the Phase 1 THINK trial for CYAD-01, their proprietary NKG2D-based CAR-T therapy. Another achievement includes the initiation of the Phase 1 alloSHRINK trial, evaluating CYAD-101, their first-in-class non-gene edited allogeneic CAR-T candidate. Furthermore, Celyad Oncology has entered into a strategic collaboration with ONO Pharmaceutical Co., Ltd., aiming to develop innovative CAR-T therapies for solid tumors. Additionally, the company has received numerous patents, reinforcing their position as a pioneer in the field of cellular immunotherapy. Celyad Oncology continues to make significant strides in advancing groundbreaking therapies to address unmet medical needs.

Celyad Oncology, a leading biopharmaceutical company, has an intriguing history and background. Founded in 2004, the company is dedicated to developing innovative CAR-T cell-based therapies for the treatment of cancer. Initially known as Cardio3 BioSciences, Celyad Oncology rebranded itself in 2015, putting a greater focus on oncology research. With a strong emphasis on cellular therapy, particularly utilizing its proprietary CAR-T technology, Celyad Oncology aims to revolutionize cancer treatment by engineering T cells to target and destroy cancer cells effectively. Through clinical trials and strategic collaborations, the company strives to provide potential breakthrough solutions for patients battling various forms of cancer worldwide. Celyad Oncology's relentless commitment and expertise drive its pursuit of improved patient outcomes.

The main competitors of Celyad Oncology in the market are bluebird bio, Inc., Fate Therapeutics, Inc., and Cellectis S.A. These companies also operate in the field of cell therapy and are known for their innovative approaches in developing advanced treatments for various diseases. However, Celyad Oncology distinguishes itself with its unique proprietary technologies, such as its allogeneic CAR-T platform and its differentiated shRNA platform. With its strong focus on product development and strategic collaborations, Celyad Oncology continues to position itself as a key player in the competitive landscape of the cell therapy market.

Celyad Oncology is primarily active in the biotechnology and healthcare industries.

Celyad Oncology is a biopharmaceutical company specializing in the development of innovative cancer treatments. The company's business model focuses on utilizing its proprietary CAR-T cell platform to engineer T-cells to target and destroy cancer cells. Through extensive research and clinical trials, Celyad aims to address unmet medical needs and improve patient outcomes by developing personalized immunotherapies. By leveraging its expertise in cell therapy and strategic partnerships, Celyad Oncology strives to revolutionize cancer treatment and provide hope for patients worldwide.

Poměr Celyad Oncology P/E je 0,34.

Koeficient Celyad Oncology tržních hodnot je 0,11.

AlleAktien kvalitní skóre pro Celyad Oncology je 3/10.

očekávané Celyad Oncology obrat je 62,50 mil. EUR.

očekávané Celyad Oncology zisk je 20,21 mil. EUR.

Celyad Oncology is an innovative biotechnology company focused on the development of cancer therapies. Its business model is centered around researching new treatment options to fight cancer. Celyad Oncology has various divisions that engage in research, development, production, and marketing of therapeutic products. One of its key divisions is CAR-T technology, which involves modifying a patient's T-cells to specifically recognize and kill cancer cells. The company is dedicated to optimizing the potential of this therapy through innovative technologies. Additionally, Celyad Oncology is involved in researching and developing other cancer treatment options such as allogeneic stem cell transplantation and the use of TCR-T cells. The company collaborates with leading research institutions and other companies to drive innovation in cancer treatment. Celyad Oncology is also involved in the production and marketing of therapeutic products, including CYAD-01, a treatment for metastatic colorectal and esophageal cancer. The company continuously strives to expand and enhance its portfolio of therapies in order to provide better healthcare to patients worldwide. Its business model relies on collaboration with other companies and institutions to advance cancer treatment. One of its key partnerships is with Novartis, a leading healthcare company, to jointly develop and market cancer therapies for the benefit of cancer patients. In summary, Celyad Oncology's business model is focused on the research, development, production, and marketing of cancer therapies. The company has various divisions dedicated to the exploration and development of new treatment options, and it already offers innovative products for cancer treatment. Celyad Oncology works closely with other companies and institutions to advance cancer treatment and provide better healthcare to patients worldwide.

Celyad Oncology vyplácí dividendu ve výši 0 EUR rozdělenou do výplat během roku.

Dividenda pro Celyad Oncology momentálně nemůže být vypočítána nebo společnost žádnou dividendu nevyplácí.

ISIN společnosti Celyad Oncology je BE0974260896.

WKN společnosti Celyad Oncology je A1W7Q9.

Ticker společnosti Celyad Oncology je CYAD.BR.

Během posledních 12 měsíců vyplatila společnost Celyad Oncology dividendu ve výši . To odpovídá dividendovému výnosu přibližně . Pro nadcházejících 12 měsíců se očekává, že Celyad Oncology vyplatí dividendu ve výši 0 EUR.

Výnos z dividend společnosti Celyad Oncology aktuálně činí .

Celyad Oncology vyplácí čtvrtletní dividendu. Ta je distribuována v měsících .

Celyad Oncology vyplácela v posledních 0 letech každý rok dividendu.

Očekává se, že v následujících 12 měsících budou dividendy ve výši 0 EUR. To odpovídá dividendovému výnosu 0 %.

Celyad Oncology je přiřazen k sektoru 'Zdraví'.

Aby ses mohl podílet na poslední dividendě Celyad Oncology ve výši 0 EUR, zaznamenané 27. 9. 2024, měl jsi mít akcii ve svém portfoliu před ex-dnem 27. 9. 2024.

Poslední dividendy byly vyplaceny dne 27. 9. 2024.

V roce 2023 společností Celyad Oncology bylo vyplaceno 0 EUR ve formě dividend.

Dividendy společnosti Celyad Oncology jsou vypláceny v EUR.